Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What's drugs got to do with it? Abbott Q3 fine post-Abbvie

This article was originally published in Clinica

Executive Summary

Abbott’s long-suffering devices business saw growth of 2% during its third fiscal quarter, helping group sales increase by the same amount as it continues to adjust to life without its Abbvie pharma division. The diagnostics division, a long-time stronghold of Abbott, was up 8%. Much of the expansion in Abbott’s devices franchise came from its medical optics unit, which posted 7% revenue growth at $276m. Abbott bolstered its ophthalmology offering earlier this year with the acquisition of OptiMedica (www.clinica.co.uk, 16 July 2013). Vascular and diabetes care sales were both flat at $747m and $319m, respectively. The former has been problematic for some time, with drug-eluting stent sales stalling – but Abbott is pinning its hopes on its bioresorbable vascular scaffold Absorb, as well as the peripheral stent gained with its purchase of IDEV Technologies in July (www.clinica.co.uk, 16 July 2013). Abbott reiterated full-year 2013 EPS guidance of $1.98-2.04 ($1.46-1.52 on a GAAP basis).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel